Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye

Xiao Dong Sun, Wei Qi Xu, Philip J. Rosenfeld

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye showed good therapeutic results. It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration, pathologic myopia and other neovascular eye diseases in short term period. The potential risks to the patients are minimal, and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.

Original languageEnglish (US)
Pages (from-to)281-284
Number of pages4
JournalChinese Journal of Ophthalmology
Volume44
Issue number3
StatePublished - Mar 1 2008
Externally publishedYes

Keywords

  • Angiogenesis inhibitors
  • Antibodies, monoclonal
  • Eye diseases
  • Neovascularization, pathologic

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye'. Together they form a unique fingerprint.

  • Cite this